Who We Are
NaMi Diagnostics is a pre-clinical stage biotechnology company developing next generation sepsis diagnostics designed to deliver rapid confirmation at emergency and critical care settings.
Our Misson
Sepsis can escalate in hours, making early detection critical to patient survival. NaMi Diagnostics is developing immune-cell based bioassays to revolutionize sepsis diagnosis. Our mission is to empower clinicians with tools that enable rapid diagnosis, timely treatment, better decisions, and improved outcomes.
Our Technology
Our diagnostic platform analyzes immune cells to detect early biochemical and biophysical changes caused by infection. In vitro data shows it can identify infection-induced inflammation within one hour, enabling sepsis detection at its earliest stage—well ahead of current clinical guidelines.
